Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
复制标题
DOI:
10.4049/jimmunol.0900475
复制
发表时间:
2009-11-15
期刊:
影响因子:
--
通讯作者:
Bernstein SH
中科院分区:
文献类型:
--
作者:
Hilchey SP;Kobie JJ;Cochran MR;Secor-Socha S;Wang JC;Hyrien O;Burack WR;Mosmann TR;Quataert SA;Bernstein SH
Our previous work has demonstrated that human follicular lymphoma (FL) infiltrating T cells are anergic, in part due to suppression by regulatory T cells. In this study, we identify pericellular adenosine, interacting with T cell-associated G protein-coupled A2A/B adenosine receptors (AR), as contributing to FL T cell hyporesponsiveness. In a subset of FL patient samples, treatment of lymph node mononuclear cells (LNMC) with specific A2A/B AR antagonists results in an increase in IFN-γ or IL-2 secretion upon anti-CD3/CD28 Ab stimulation, as compared with that seen without inhibitors. In contrast, treatment with an A1 AR antagonist had no effect on cytokine secretion. As the rate limiting step for adenosine generation from pericellular ATP is the ecto-ATPase CD39, we next show that inhibition of CD39 activity using the inhibitor ARL 67156 partially overcomes T cell hyporesponsiveness in a subset of patient samples. Phenotypic characterization of LNMC demonstrates populations of CD39-expressing CD4+ and CD8+ T cells, which are overrepresented in FL as compared with that seen in normal or reactive nodes, or normal peripheral blood. Thirty percent of the FL CD4+CD39+ T cells coexpress CD25high and FOXP3 (consistent with regulatory T cells). Finally, FL or normal LNMC hydrolyze ATP in vitro, in a dose- and time-dependent fashion, with the rate of ATP consumption being associated with the degree of CD39+ T cell infiltration. Together, these results support the finding that the ATP-ectonucleotidase-adenosine system mediates T cell anergy in a human tumor. In addition, these studies suggest that the A2A/B AR as well as CD39 are novel pharmacological targets for augmenting cancer immunotherapy.
登录
查看更多内容
DOI:
10.1073/pnas.0605251103
发表时间:
2006-08-29
影响因子:
11.1
作者:
Ohta, Akio;Gorelik, Elieser;Sitkovsky, Michail
通讯作者:
Sitkovsky, Michail
影响因子:
4.8
作者:
Csoka, Balazs;Himer, Leondra;Hasko, Gyoergy
通讯作者:
Hasko, Gyoergy
影响因子:
4.4
作者:
Naganuma, Makoto;Wiznerowicz, Elizabeth B.;Ernst, Peter B.
通讯作者:
Ernst, Peter B.
DOI:
10.1073/pnas.87.21.8267
发表时间:
1990-11-01
影响因子:
11.1
作者:
FILIPPINI, A;TAFFS, RE;SITKOVSKY, MV
通讯作者:
SITKOVSKY, MV
影响因子:
20.3
作者:
Eltzschig, Holger K.;Koehler, David;Colgan, Sean P.
通讯作者:
Colgan, Sean P.